AKR1CL1 Inhibitors
AKR1CL1 inhibitors are a class of chemical compounds that target and inhibit the activity of the aldo-keto reductase family 1, member C-like 1 (AKR1CL1) enzyme. AKR1CL1 belongs to the aldo-keto reductase (AKR) superfamily, which plays a significant role in catalyzing the reduction of aldehydes and ketones to their corresponding alcohols using NADPH as a cofactor. These enzymes are involved in various biochemical processes, including the metabolism of steroids, sugars, and xenobiotics. AKR1CL1 inhibitors are specifically designed to disrupt the catalytic activity of this enzyme by binding to its active site. They typically function by mimicking the structure of the enzyme's natural substrates or transition states, allowing them to engage key catalytic residues and cofactors, such as NADPH, thereby preventing the reduction reaction from occurring.
The development of AKR1CL1 inhibitors relies on a detailed understanding of the enzyme's structure and its interaction with substrates. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy are commonly used to determine the 3D structure of the enzyme, particularly its active site, which is critical for the rational design of inhibitors. The inhibitors may feature chemical groups like hydroxyls, carbonyls, or aromatic rings, which help them bind to the active site through hydrogen bonding, hydrophobic interactions, or π-π stacking with the enzyme's residues. Computational approaches, including molecular docking and molecular dynamics simulations, are often employed to predict the binding affinity of potential inhibitors and optimize their specificity. In some cases, allosteric inhibitors may also be developed to bind at sites away from the active site, inducing conformational changes that reduce the enzyme's activity. By selectively inhibiting AKR1CL1, these compounds are valuable for investigating the enzyme's role in various metabolic pathways and for advancing the understanding of its biochemical function in the aldo-keto reductase family.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $26.00 $77.00 $151.00 $303.00 | 1 | |
Flufenamic Acid is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits certain isoforms of the aldo-keto reductase (AKR) family. AKR1CL1, being a member of this family, is affected due to the drug's ability to interfere with the NADPH binding site, inhibiting its activity. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Indomethacin is another NSAID that has been shown to competitively inhibit AKR1CL1 by binding to its active site. This binding prevents the reduction of aldehydes and ketones, which are the typical substrates of AKR1CL1, thereby decreasing the enzymatic activity of AKR1CL1. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac, a sulfoxide prodrug that gets reduced in vivo to an active sulfide form, is known to inhibit various aldo-keto reductases. It can impede the catalytic mechanism of AKR1CL1 by binding to its active site, thus reducing its ability to process substrates. | ||||||
Vitamin K3 | 58-27-5 | sc-205990B sc-205990 sc-205990A sc-205990C sc-205990D | 5 g 10 g 25 g 100 g 500 g | $25.00 $35.00 $46.00 $133.00 $446.00 | 3 | |
Menadione acts as a substrate for AKRs but can also serve as an inhibitor. At high concentrations, Menadione can lead to the oxidation of the catalytic cysteine in AKR1CL1, which is essential for the enzyme's activity, resulting in its inhibition. | ||||||
Fomepizole | 7554-65-6 | sc-252838 | 1 g | $74.00 | 1 | |
Fomepizole, an alcohol dehydrogenase inhibitor, can also inhibit AKR1CL1 by competing with its substrates for the active site. This competition effectively reduces the enzyme's functional activity as it prevents the reduction of physiological substrates. | ||||||
Mefenamic acid | 61-68-7 | sc-205380 sc-205380A | 25 g 100 g | $104.00 $204.00 | 6 | |
Mefenamic Acid, also part of the NSAID family, inhibits AKR1CL1 by binding to the enzyme's active site similarly to other NSAIDs. This reduces AKR1CL1's ability to catalyze the reduction of aldehydes and ketones, leading to decreased enzymatic activity. | ||||||
Ethacrynic acid | 58-54-8 | sc-257424 sc-257424A | 1 g 5 g | $49.00 $229.00 | 5 | |
Ethacrynic Acid is a diuretic that can irreversibly inhibit human aldo-keto reductases by covalently modifying the cysteine in the active site. This irreversible binding can lead to a significant decrease in AKR1CL1 activity. | ||||||
Danazol | 17230-88-5 | sc-203021 sc-203021A | 100 mg 250 mg | $90.00 $233.00 | 3 | |
Danazol, a synthetic steroid, inhibits AKR1CL1 by mimicking its substrates and binding to its active site. This competitive inhibition results in a reduction of the enzyme's ability to process physiological substrates. | ||||||